Loading stock dossier…
Beta Drugs Limited is a small-cap Healthcare stock trading at a price-to-earnings of 34.7, placing it in the 58th percentile of Healthcare sector (lower is cheaper). Its return on equity of 18.8% sits at the 78th percentile of the same cohort. The composite smart-money score (insider + FII/DII flow + block deals + mutual-fund accumulation) is currently in the "NEUTRAL" bucket.
Up to 10 years of daily closes, with vertical hairlines marking the dates of earnings announcements (accent), ownership inflections (red), and dividend ex-dates (faint). Hover any hairline for the event label.
Hover the chart for a date+price readout; click any vertical hairline to pin its event label.
Two views of how the market is valuing this stock. Implied growth reverse-engineers the annual growth rate baked into the current P/E. Snowflake places the stock on five orthogonal axes from MintByte's in-house model.
One rupee invested at the start, plotted on a log scale, with closes back-adjusted for every stock split and bonus issue across the window. The headline reads the cumulative outcome; the CAGR badge annualises it.
Every historical drawdown of 12% or more in the available 10 years of EOD data. The left bar shows depth; the right bar shows months until the price made a new all-time high.
Two views of recent event-driven price action: the earnings-reaction grid shows how the market traded the day after each of the last 8 quarterly results, and the insider heat strip shows weekly net insider buying/selling over the last 90 days.
| Date | Insider | Category | Type | Qty |
|---|
Equity prices and ratios are computed from NSE / BSE end-of-day data. No content on this page constitutes a buy / sell / hold recommendation. MintByte is an AMFI-registered mutual fund distributor (ARN-314872). MintByte does not issue buy/sell recommendations on specific securities — the site is an educational data and analytics platform. Not investment advice. Methodology · How we earn.
Implied growth and ROE are derived from a simplified Gordon-growth model: g = (PE × r − 1) / (PE + 1) with cost-of-equity r = 12% (a standard India-equity assumption). This is a thought-experiment, not a forecast. Not investment advice.
Each axis is a 0–5 score from MintByte's snowflake compute. Value = valuation cheapness · Future = growth potential · Past = track record · Health = balance-sheet strength · Dividends = payout & yield.
No signal at present — see methodology for the criteria.
SWOT items are auto-derived from quantitative factor scores, Smart Money sentiment, and shareholding snapshot. They are not investment advice.
Each factor is computed monthly from the in-house model and bucketed into quintiles across the active equity universe. Q1 = top quintile on that factor (favourable position) · Q5 = bottom quintile.
T+1 = close one trading session after the result announcement (or next trading day).
Insider transactions grouped by week, net of buys vs sells in rupee value. Colour saturation scales to the largest-net week in the window. SEBI Reg 7(2) filings.
| Value |
|---|
| 13 Nov 2025 | Neeraj Batra | Promoters | SELL | 1,85,115 | ₹31Cr |
| 29 Mar 2025 | Rahul Batra | Promoters | BUY | 1,982 | ₹0 |
| 20 Jan 2023 | Rahul Batra | Promoters | BUY | 2,400 | ₹16L |
| 20 Jan 2023 | Rahul Batra | Promoters | BUY | 2,400 | ₹16L |
| 8 Nov 2021 | Rahul Batra | Promoters | BUY | 2,800 | ₹17L |
| 16 Nov 2020 | Vijay Kumar Batra | Promoters | BUY | 6,400 | ₹8L |
| 1 Sept 2020 | Vijay Kumar Batra | Promoters | BUY | 50,400 | ₹43L |
| 18 Mar 2020 | Vijay Kumar Batra | Promoters | BUY | 20,000 | ₹9L |
| 13 Mar 2020 | Vijay Kumar Batra | Promoters | BUY | 43,200 | ₹21L |
| 29 Oct 2019 | Vijay Kumar Batra | Promoters | BUY | 10,400 | ₹10L |
| 11 Jul 2019 | Vijay Kumar Batra | Promoter Group | BUY | 26,400 | ₹25L |
| 2 Jul 2019 | Vijay Kumar Batra | Promoters | BUY | 1,83,648 | ₹2Cr |
| 1 Dec 2018 | Vijay Kumar Batra | Promoters | BUY | 48,800 | ₹36 |